Tag: Press Releases
-
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
-
Biodesix Advances ORACLE Registry for Lung Nodule Cancer Test
-
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
-
Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules in New CHEST Data Publication
-
Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
-
Biodesix Extends Lung Franchise with Acquisition of Integrated Diagnostics
-Acquired assets include the XL2 blood-based test designed to improve lung cancer diagnosis–
-
2018 Preliminary Private Payor Rate-Based Payment Amounts Released for Clinical Diagnostic Laboratory Tests; Biodesix Commends CMS for Committing to On-Time PAMA Implementation
Biodesix today commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests, including Biodesix’s VeriStrat® test. The CMS has announced that rates will be finalized in November 2017, following a public comment period, and that the new rates are scheduled to become effective on January 1,…
-
Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy
Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy
-
Heinrich Roder to speak at 6th International Conference on Bioinformatics & Systems Biology
WHAT: Dr. Heinrich Roder, Biodesix’ CTO and chair of the conference’s computational systems biology program, will speak on “Bridging the gap: From hypothesis-independent tests to understanding of biological mechanisms”, to introduce the Computational Systems biology track at the 6th International Conference on Bioinformatics & Systems Biology.
-
Biodesix Presentation at Molecular Med Tri-Conference: “Blood-Based Cancer Immunotherapy Diagnostics”
Chief Technology Officer for Biodesix, Inc., Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.